Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on January 24, 2017. The report covers events occurring on that date, specifically the publication of clinical study results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a scientific milestone rather than financial performance.
Material Changes
The material event reported is the publication of study results in Clinical Cancer Research. The study demonstrates the analytical and clinical performance of Trovagene's Trovera® urine and blood liquid biopsy tests. These tests are designed to quantitatively assess KRAS mutations in patients with diverse advanced cancers.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the clinical study. The primary disclosure is the validation of the company's diagnostic technology through peer-reviewed publication.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed study data.
- Confirm the specific performance metrics of the Trovera® tests as published in Clinical Cancer Research.
- Review subsequent filings for any financial impact or regulatory approvals resulting from these study results.